This study is designed to analyze the frequency and incidence rate of pulmonary complications in JIA participants who received biological DMARDs and non-biologic DMARDs. The participants having evidence of of a prescription or administration of one of the biologic or non-biologic DMARDs will be included in five different treatment groups. Data from the Thomson Reuters MarketScan® Commercial Claims and Medicare Supplemental Databases will be used to estimate the incidence rate of pulmonary complications.
Study Type
OBSERVATIONAL
Enrollment
4,557
Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
Percentage of participants with pulmonary arterial hypertension
Time frame: up to the end of the study (up to overall period of 12 years)
Percentage of participants with interstitial lung disease
Time frame: up to the end of study (up to overall period of 12 years)
Percentage of participants with alveolar proteinsis
Time frame: up to the end of study (approximately 2.2 years)
Percentage of participants with lipoid pneumonia
Time frame: up to the end of study (up to overall period of 12 years)
Percentage of participants with pulmonary hypertension
Time frame: up to the end of study (up to overall period of 12 years)
Percentage of participants with overall composite pulmonary complications
Time frame: up to the end of study (up to overall period of 12 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.